



Financial Results for 3rd Quarter of FY2021

February 7, 2022
Sumitomo Bakelite Co., Ltd.

Outline of Financial Results for 3rd Quarter of FY2021

Financial Results for 3rd Quarter of FY2021 (Y/Y)

[Unit: Billion yen]

	3Q of FY2020 (1)	3Q of FY2021 (2)	Variance (Y/Y)	
			(2)-(1)	Ratio
Revenue	149.0	195.9	46.9	31.5%
Business Profit	11.5	21.2	9.7	84.0%
Operating Profit	18.6	21.0	2.4	13.1%
Profit attributable to owners of parent	11.8	16.1	4.3	36.8%

* "Business profit" is calculated by deducting "Cost of sales" and "Selling, general and administrative expenses" from "Revenue".

* Kawasumi Laboratories, Inc. became our consolidated subsidiary from 3Q of FY2020, and changed its name to SB-Kawasumi Laboratories, Inc. on October 1, 2021.

Ref. Results of Kawasumi Laboratories for 1H


Revenue: 10.5 billion yen

Business Profit: 0.7 billion yen

FOREX	3Q - FY2020	3Q - FY2021
JPY / USD	105.87	111.38
JPY / EUR	122.30	130.85


Revenue and Business Profit by Business Segment (Y/Y)

(Unit: Billion yen)



Quarterly Revenue by Business Segment

(Billion yen)



Semiconductor Materials

Continued upward trend in revenue due to brisk global demand for semiconductors

High Performance Plastics


Remaining stable conditions of revenue thanks to progress in passing higher raw material prices to our selling prices despite of volume decrease due to impacts of reducing automobile production caused from semiconductor shortage.

Quality of Life Products

Steady demand in films & sheets for pharmaceutical use followed by generic manufacturer. In medical devices, favorable launch of SB-Kawasumi Laboratories, Inc. on October 1.

Analysis of Business Profit (Y/Y)

(Billion yen)



Segment	Sales	Sales & raw material price gap	Fixed cost	FOREX	Total
Semiconductor Materials	+ 6.2	+ 0.8	1.3	+ 0.4	+ 6.1
High Performance Plastics	+ 5.3	1.4	1.2	+ 0.2	+ 2.8
Quality of Life Products	+ 7.7	0.7	5.8	0.0	+ 1.1
Others	0.0	0.0	0.3	0.0	0.4

Financial Forecasts for FY2021

Financial Forecasts for FY2021


No change from announcement
on October 27, 2021

(Billion yen)


	FY2020 Actual Result (1)	FY2021 Current Forecast (2)	Variance	
			(2) - (1)	Ratio (%)
Revenue	209.0	250.0	41.0	19.6
Business Profit	16.6	25.0	8.4	50.2
Profit attributable to owners of parent	13.2	17.6	4.4	33.4

* "Business profit" is calculated by deducting "Cost of sales" and "Selling, general and administrative expenses" from "Revenue".

Revenue




Business Profit



Dividends

No change from announcement on October 27, 2021

Dividend Forecasts (FY2021): 100.00 yen per share (Interim 50 yen, Year-end 50 yen)



(yen per share)	FY2017	FY2018	FY2019	FY2020	FY2021 (Forecast)
Interim	30.00	37.50	45.00	30.00	50.00
Year-end	30.00	37.50	30.00	45.00	50.00
Total	60.00	75.00	75.00	75.00	100.00

* Although we carried out a share consolidation at a ratio of one share for every five shares on 1 October 2018, figures in FY2017 and FY2018 is shown after such share consolidation.

Appendix (1)

1) Summary of Results and Forecasts

(Unit: Billion Yen)

	March 2021 [FY2020] Results					March 2022 [FY2021]				Full Year Forecasts (Apr-Mar)
	1Q (Apr-Jun)	2Q (Jul-Sep)	3Q (Oct-Dec)	4Q (Jan-Mar)	Full Year (Apr-Mar)	1Q - 3Q Results			Total	
						1Q (Apr-Jun)	2Q (Jul-Sep)	3Q (Oct-Dec)		
Revenue	43.7	46.5	58.8	60.0	209.0	62.7	65.6	67.6	195.9	250.0
Business profit (*1)	2.4	2.5	6.7	5.1	16.6	6.7	7.0	7.5	21.2	25.0
Profit before tax	2.4	1.8	10.3	1.6	16.1	6.9	7.1	7.8	21.8	-
Profit attributable to owners of parent	1.9	1.3	8.6	1.4	13.2	5.2	5.0	5.9	16.1	17.6

2) Revenue and Business Profit by Business Segment

(Unit: Billion Yen)

	March 2021 [FY2020] Results					March 2022 [FY2021]				Full Year Forecasts (Apr-Mar)
	1Q (Apr-Jun)	2Q (Jul-Sep)	3Q (Oct-Dec)	4Q (Jan-Mar)	Full Year (Apr-Mar)	1Q - 3Q Results			Total	
						1Q (Apr-Jun)	2Q (Jul-Sep)	3Q (Oct-Dec)		
[Semiconductor Materials]										
Revenue	12.6	13.3	15.1	16.2	57.3	17.5	19.1	19.9	56.5	73.1
Business profit (*1)	2.0	1.9	2.7	2.8	9.4	3.7	4.4	4.6	12.7	16.5
[High Performance Plastics]										
Revenue	14.6	16.2	20.3	21.4	72.6	23.1	22.2	22.8	68.1	86.5
Business profit (*1)	-0.3	-0.1	2.3	1.6	3.5	2.0	1.3	1.4	4.7	5.1
[Quality of Life Products]										
Revenue	16.3	16.9	23.3	22.1	78.6	21.9	24.3	24.8	71.0	89.9
Business profit (*1)	1.4	1.3	2.4	1.4	6.6	1.8	2.1	2.4	6.3	6.8
[Others]										
Revenue	0.1	0.1	0.1	0.2	0.6	0.1	0.1	0.1	0.4	0.6
Business profit (*1)	-0.7	-0.7	-0.7	-0.7	-2.9	-0.9	-0.8	-0.8	-2.5	-3.5
[Total]										
Revenue	43.7	46.5	58.8	60.0	209.0	62.7	65.7	67.6	195.9	250.0
Business profit (*1)	2.4	2.5	6.7	5.1	16.6	6.7	7.0	7.6	21.2	25.0

(*1) "Business profit" is calculated by deducting "Cost of sales" and "Selling, general and administrative expenses" from "Revenue".

Appendix (2)

3) Management Index

	March 2021 [FY2020] Results					March 2022 [FY2021]				
	1Q -3Q Results				Full Year (Apr-Mar)	1H (Apr-Sep) Results				Full Year Forecasts (Apr-Mar)
	1Q (Apr-Jun)	2Q (Jul-Sep)	3Q (Oct-Dec)	Total		1Q (Apr-Jun)	2Q (Jul-Sep)	3Q (Oct-Dec)	Total	
Earnings per share (Yen)	39.40	27.83	183.38	250.60	280.46	111.43	106.95	124.55	342.93	374.02
ROA (%)	3.4	2.5	13.0	6.3	5.1	8.0	8.1	8.9	8.3	6.9
ROE (%)	4.2	2.9	18.8	8.6	7.0	10.4	9.8	11.0	10.3	8.4
Ratio of equity attributable to owners of parent (%)	62.5	59.6	56.8	56.8	57.9	58.5	59.6	61.4	61.4	61.6
Capital expenditure (Billion Yen)	2.0	2.5	2.5	6.9	11.1	4.2	3.2	3.1	10.5	15.0
Depreciation (Billion Yen)	2.8	2.8	3.3	8.9	12.3	3.3	3.3	3.4	10.0	13.4
R&D expenses (Billion Yen)	2.4	2.5	2.7	7.6	10.4	2.6	2.6	2.8	8.0	10.8
Financial Liability balance at year end (Billion Yen)	52.9	67.5	80.6	80.6	76.7	74.9	68.3	63.3	63.3	62.8
Net financial income and expenses (*1) (Billion Yen)	0.3	0.0	0.2	0.5	0.7	0.3	0.1	0.3	0.6	0.8
No. of employees	5,865	5,699	8,070	8,070	7,937	7,941	7,891	7,900	7,900	7,970

(*1) Excluding such as "Loss (gain) on step acquisition" associated with additional acquisition of Kawasumi Laboratories' shares

This presentation material contains forward-looking statements that are based on management's estimates, assumptions and projections as of February 7, 2022.

Some factors, which include, but are not limited to, the risks and uncertainty associated with the worldwide economy, competitive activity and currency fluctuation, could cause actual results to differ materially from expectations.

** Our FY2021 runs from April 1, 2021 through March 31, 2022.*